Antidepressants in Bipolar Depression: Still Controversial After All These Years

被引:1
|
作者
Mansur, Rodrigo B. [1 ,2 ,3 ]
机构
[1] Univ Toronto, Univ Hlth Network, Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] 399 Bathurst St, 9M316D, Toronto, ON M5T 2S8, Canada
基金
加拿大健康研究院;
关键词
TREATMENT ENHANCEMENT PROGRAM; MANIC SYMPTOMS; II DEPRESSION; DOUBLE-BLIND; DISORDER; LITHIUM; MONOTHERAPY; METAANALYSIS; VENLAFAXINE; EFFICACY;
D O I
10.3928/00485713-20230119-02
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The use of antidepressants in the treatment of bipolar disorder (BD) has been one of the more enduring controversies in the field. Antidepres-sants continue to be one of the most widely used classes of psychotropic agents in BD and are still prominent-ly featured in most treatment guide-lines, despite the limited and incon-sistent evidence supporting their safety and efficacy in the treatment and prevention of episodes of bipolar 1 depression. Herein, the authors re-view the clinical and meta-analytical evidence on the effi cacy and safety of antidepressants in BD types 1 and 2. Clinicians should be aware of the potential risks and benefits of anti-depressants for patients with BD, as well as the scenarios and patients' characteristics that can affect treat-ment outcomes. [Psychiatr Ann. 2023;53(2):63-67.]
引用
收藏
页码:63 / 67
页数:5
相关论文
共 50 条